WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback